Incannex Healthcare Limited — Form 20-F Summary
Reporting period: Fiscal year ended June 30, 2022 (not a 2021 fourth-quarter filing). The company is an Australian clinical-stage pharmaceutical developer focused on cannabinoid and psychedelic therapies. Financial statements are audited and presented in Australian dollars (A$) under IFRS. ADSs began trading on Nasdaq in February 2022; each ADS represents 25 ordinary shares.
Financial and operating results
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | A$0 | A$1.90 million |
| Other income | A$0.79 million | A$0.08 million |
| Total expenses | A$15.69 million | A$13.35 million |
| Net and comprehensive loss | A$14.90 million | A$11.37 million |
| Basic and diluted loss per share | 1.25 cents | 1.16 cents |
| Net cash used in operating activities | A$12.81 million | A$6.91 million |
| Cash and cash equivalents at year-end | A$37.50 million | A$9.12 million |
| Total liabilities | A$2.01 million | A$0.76 million |
FY2022 revenue ceased after the company ended its cannabinoid-product distribution arrangement to concentrate on drug development. The A$0.79 million of other income was primarily an Australian refundable R&D tax offset. R&D expense rose 13% to A$5.37 million; legal, compliance and regulatory expense increased to A$3.56 million from A$1.23 million, partly reflecting Nasdaq listing costs. Loss widened 31%, mainly due to higher development, regulatory and employee costs.
Financing activities provided A$41.18 million, including A$40.27 million from option exercises. The balance sheet reported no borrowings; liabilities were principally payables and accruals. Management said cash was expected to fund operations through the end of 2024, while warning that this forecast is uncertain and further funding will be needed for longer-term development. The company reported no material contingent liabilities or capital commitments at year-end. Margins are not meaningful given the absence of FY2022 revenue and the company’s development-stage operations.
Development, material events and outlook
- Pipeline: Lead programs include IHL-42X for obstructive sleep apnea (OSA), IHL-216A for traumatic brain injury, IHL-675A for inflammatory conditions, and psilocybin-assisted psychotherapy for generalized anxiety disorder. The company also reported a broader cannabinoid portfolio.
- IHL-42X: In a small Phase 2 proof-of-concept crossover study, 10 participants completed treatment periods. The filing reports reductions in apnea-hypopnea index (AHI), with low and medium doses statistically significant versus baseline at the group level. These preliminary results require confirmation in larger trials; the company was preparing an FDA IND and pivotal Phase 2 study.
- IHL-216A and IHL-675A: The filing describes encouraging animal and laboratory findings, but some preclinical results were not statistically analyzed. They do not establish clinical efficacy. FDA feedback and additional manufacturing, safety and clinical work remained necessary.
- Psilocybin program: The Phase 2 exploratory GAD study had enrolled 30 participants by the third quarter of 2022. An interim review was planned to inform further trial development; no efficacy outcome was reported in the filing.
- APIRx acquisition after year-end: On August 5, 2022, the company acquired APIRx Pharmaceutical USA, LLC in an all-share transaction. The filing describes consideration of approximately 218.2 million ordinary shares; its acquisition disclosures give slightly different share counts and prices, which investors should reconcile. The acquired portfolio included 19 granted and 23 pending patents. The acquisition was accounted for as an asset acquisition, not a business combination.
- Outlook and key risks: The company expects continued operating losses and rising development costs, has no approved products or material ongoing product revenue, and may need additional capital. Key uncertainties include trial safety and efficacy, patient recruitment, regulatory approval, controlled-substance requirements, third-party manufacturing and supply, intellectual-property protection, reimbursement, dilution, and foreign-currency exposure. Management had not established that expedited FDA pathways would be available.
Investor facts to verify
- Review the audited financial statements and cash runway assumptions, including planned trial spending and the timing and terms of any future financing.
- Check subsequent clinical-trial results, protocols, sample sizes, statistical analyses and FDA requirements; distinguish preliminary or preclinical findings from demonstrated clinical benefit.
- Reconcile the APIRx acquisition consideration, share count, valuation and dilution, and assess integration costs and the acquired assets’ development status.
- Confirm the current ordinary-share count, outstanding options and other potential dilution. At June 30, 2022, 1.292 billion ordinary shares were outstanding.
- Assess dependence on external manufacturers and collaborators, controlled-substance licensing, patent scope, and the company’s ability to fund programs through approval and commercialization.